Opus Genetics, Inc. is a clinical-stage ophthalmic biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The company's pipeline consists of seven adeno-associated virus (AAV)-based gene therapy programs targeting specific genetic mutations, including OPGx-LCA5 for Leber congenital amaurosis, OPGx-BEST1 for bestrophinopathy, and candidates for RHO, CNGB1, RDH12, NMNAT1, and MERTK. Additionally, the company markets Phentolamine Ophthalmic Solution, an FDA-approved small-molecule therapy for pharmacologically induced mydriasis with potential indications in presbyopia and low-light visual disturbances. Founded in February 2018 as Ocuphire Pharma, Inc., the company acquired the assets of Ocularis Pharma, LLC and merged with Rexahn Pharmaceuticals, Inc. before acquiring the private entity Opus Genetics Inc. in October 2024. The company collaborates with academic institutions such as the University of Pennsylvania, Harvard Medical School, and the University of Florida for its gene therapy research. Its therapies are designed for subretinal injection to address the underlying genetic causes of severe retinal disorders.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage opusgtx.com
Sector Healthcare IR page ir.opusgtx.com
Tags
gene therapy, ophthalmology, inherited retinal diseases, leber congenital amaurosis, retinitis pigmentosa, bestrophinopathy, adeno-associated virus, small-molecule therapy, mydriasis, presbyopia, OPGx-LCA5, OPGx-BEST1, Phentolamine Ophthalmic Solution, Ocuphire Pharma Inc., Ocularis Pharma LLC, Rexahn Pharmaceuticals Inc., Apexian Pharmaceuticals Inc., APX3330, LUXTURNA
Press page —

Metrics

Valuation  
Market cap $ 373.542M
Market cap (USD) $ 373.542M
P/E -2.53
PEG —
P/BV 9.72
P/S 47.20
P/OCF -7.69
P/FCF -10.60
Dividend yield —
Turnover / mcap —
Returns  
ROE -449.4%
ROI -301.0%
ROIC -175.7%
Profit margin -349.3%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 92.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 59
Quality score -70.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008
Revenue 14.196M 10.992M 19.049M 39.85M 589K — 3M — — — — — 0 — 0 0 — —
Net profit -49.591M -57.532M -9.986M 17.888M -56.693M -24.62M -8.635M -14.369M -25.295M -9.307M -14.385M -18.522M -9.499M -6.227M -11.345M -14.022M — —
Free cash flow -35.253M -25.576M -1.112M 14.314M -19.37M -6.797M — — — — — — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008
Share price 2.01 1.19 3.01 3.53 3.73 6.49 1.89 — — — — — — — — — — —
Price performance 12m 0.69 -0.6 -0.15 -0.05 -0.42 2.44 — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — 0.00 0.00 1.3M 926,000 3.56M 2M
↳ YoY growth -28.7% +284.8% -44.0%
Borrowings, current (USD) — — — — 0.00 538,000 0.00 — — —
Borrowings, non-current (USD) — — — — — — — — 0.00 1.13M
Lease liabilities (USD) — — — 203,370 — — — — — —
Cash and deposits (USD) 11.6M 8.9M 8.74M 9.22M 16.4M 24.5M 42.6M 50.5M 30.3M 45.1M
Right-of-use assets (USD) — — — 203,348 — — — — — —
Net debt (borrowings + leases - cash) (USD) — — — — -16.4M -24M -42.6M — -30.3M -44M
Cash flow detail
Operating cash flow (USD) -13.2M -15.4M -18.8M -10.3M -6.8M -19.4M 14.3M -1.11M -25.6M -35.3M
Purchases of property, plant and equipment (USD) — — — -25,000 0.00 — — — — —
Change in receivables (cash effect) (USD) — — — — — 0.00 -1.3M 372,000 -2.64M 1.57M
Change in payables (cash effect) (USD) -778,798 1.35M -81,376 -1.89M 792,000 381,000 -515,000 1.08M 220,000 7,000
Interest paid (cash effect) (USD) — — — 0.00 0.00 -2,000 -9,000 0.00 0.00 0.00
Income taxes paid (cash effect) (USD) — — — 0.00 0.00 0.00 0.00 -344,000 0.00 0.00
Share-based compensation (USD) 1.41M 1.04M 1.23M 456,750 1.51M 1.91M 1.81M 3.51M 3.36M 3.4M
Operating cash flow before change in receivables (USD) — — — — — -19.4M 15.6M -1.48M -22.9M -36.8M
Free cash flow (OCF - PPE - intangibles) (USD) — — — -3.62M -6.8M — — — — —
Income detail
Research and development expense (USD) 10.1M 10.7M 13.1M 5.48M 6.65M 15.2M 14.4M 17.7M 26.9M 30.8M
↳ 5y CAGR -3.4% +25.9% +32.1% -4.8% -11.4% +8.5% +6.0% +6.1% +37.4% +35.9%
Total comprehensive income (USD) -9.3M -25.3M -14.3M -8.62M -24.6M -56.7M 17.9M -9.99M -57.5M -49.6M
Comprehensive income to owners (USD) -9.3M -25.3M -14.3M -8.62M -24.6M -56.7M 17.9M -9.99M -57.5M -49.6M
Provision for credit losses (USD) — — — — — 0.00 0.00 0.00 0.00 0.00
Credit cost ratio (credit losses / average receivables) (%) — — — — — — 0.0% 0.0% 0.0% 0.0%
Reported Feb 24, 2017 Mar 9, 2018 Mar 7, 2019 Mar 11, 2021 Mar 24, 2022 Mar 30, 2023 Mar 30, 2023 Mar 8, 2024 Aug 13, 2025 Mar 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

OPGx-LCA5 Registrational Phase 3 Trial Fully Enrolled with Initiation of Dosing Expected in Q4 2026

FDA Clearance of IND for OPGx-RDH12, with Phase 1/2 Trial Dosing Planned for Q4 2026

FDA Approval of Phentolamine Ophthalmic Solution 0.75% for Presbyopia Triggers Milestone Payment

Cash Runway into 2029 Expected to Support Multiple Clinical Inflection Points and

Opportunities for Priority Review Vouchers

RESEARCH TRIANGLE PARK, N.C. – November 10, 2026 - Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced financial results for the third quarter ended September 30, 2026, and provided a corporate update.

“The last several months have marked a period of tremendous advancement for our leading gene therapy programs,” said George Magrath, M.D., Chief Executive Officer of Opus Genetics. “Positive Cohort 1 data from our Phase 1/2 trial of OPGx-BEST1 provide important evidence of its potential to improve both visual function and retinal structure in patients with BEST1-related retinal disease.

October 29, 2026 7:00am EDT

Appointments strengthen scientific leadership and operational capabilities as Opus advances its pipeline of gene therapies for inherited retinal diseases

RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc . (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the appointments of Andrew Murphy, Ph.D., as Chief Scientific Officer and Jamie Lynne Hart, M.S., M.P.H., as Executive Director, Executive Operations. These appointments strengthen Opus Genetics’ scientific and operational capabilities as the Company advances its pipeline of gene therapies for inherited retinal diseases.

“As we continue to advance our clinical programs and expand our pipeline, strengthening our scientific leadership and operational capabilities is essential to supporting our next phase of growth,” said George Magrath, M.D., Chief Executive Officer, Opus Genetics. “Andy brings deep expertise in gene therapy research, AAV vector development and translational science that we expect will be invaluable as we advance our programs toward important clinical milestones. Jamie brings extensive experience in executive operations and organizational coordination, and as well as significant experience in the ophthalmology sector, which we believe will help us execute effectively across our growing organization. We are pleased to welcome both to the Opus Genetics team.”

Andrew Murphy, Ph.D., brings more than 18 years of biotechnology experience spanning gene therapy research, translational development and regulatory advancement. Prior to joining Opus Genetics, Dr. Murphy served as Senior Vice President of Research and Early Development at Kriya Therapeutics, where he led AAV vector design, research, genomics and data science activities, advancing gene therapy candidates across ophthalmology, metabolic, neurological and rare diseases.

Throughout his career, he has supported seven therapeutic programs through Phase 1 IND or CTA submissions, including five during his tenure at Kriya Therapeutics. Previously, Dr. Murphy founded Kitty Hawk Biosciences, a gene therapy consultancy focused on AAV vector characterization and potency assay development, and held scientific leadership positions at KBI Biopharma, Duke University Medical Center, ProteoVec and Liquidia Technologies. He holds a Ph.D. in Chemistry from Stanford University and a B.A. in Chemistry from Oberlin College.

Jamie Lynne Hart, M.S., M.P.H., brings more than 15 years of experience in biotechnology and ophthalmology, spanning executive operations, corporate development, medical affairs and clinical research. Prior to joining Opus Genetics, Ms. Hart served as Chief of Staff to the Chief Executive Officer at Apellis Pharmaceuticals (now Biogen), where she partnered with executive leadership and the Board of Directors to drive corporate strategy, portfolio prioritization and cross-functional execution across research, development and commercialization. Previously, she held several leadership positions at Ocular Therapeutix, including Director of Corporate Development and Alliance Management and Director of Medical Affairs, where she supported strategic partnerships, pipeline expansion and the company's transition to commercialization. She was also on the medical affairs team at Shire Pharmaceuticals (now Takeda).

Earlier in her career, she was focused on clinical research in rare diseases and ophthalmic drug development. She has published extensively in uveitis, an orphan ophthalmic condition. Ms. Hart holds a Master of Science and a Master of Public Health from Tufts University School of Medicine, as well as undergraduate degrees from Boston University.

The appointments come as Opus Genetics continues to advance its ophthalmic gene therapy programs, including OPGx-BEST1 for BEST1-associated retinal disease, OPGx-LCA5 for Leber congenital amaurosis caused by mutations in the LCA5 gene and OPGx-RDH12 for RDH12-associated Leber congenital amaurosis. The Company remains focused on progressing its pipeline and developing innovative treatments for patients with inherited retinal diseases who have limited therapeutic options.

Forward-Looking Statements

This press release contains certain statements that are not statements of historical fact and are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “strive,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Such statements include, but are not limited to, statements related to the anticipated contributions of the Company’s newly appointed Chief Scientific Officer and Executive Director, Executive Operations and their potential to support the Company’s next phase of growth; the Company’s plans to advance its clinical programs and expand its pipeline; the Company’s expectations with respect to its growth and operational execution; and the Company’s expectations regarding its business prospects and results of operations. The forward-looking statements contained herein are subject to certain risks and uncertainties posed by many factors and events that could cause the Company’s actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in the Company’s other filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Except as required by law, the Company undertakes no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise.

About Opus Genetics

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with OPGx-RDH12 cleared to enter the clinic, and additional candidates targeting, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, N.C. For more information, visit www.opusgtx.com .

October 21, 2026 7:00am EDT

FDA clearance enables clinical development of OPGx-RDH12 for RDH12-associated Leber congenital amaurosis, a rare inherited retinal disease that causes progressive vision loss beginning in early childhood

Strategic collaboration with the Global RDH12 Alliance supports the development of a potential treatment for this disease with high unmet need

RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc.

(Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for OPGx-RDH12, an investigational gene therapy for the treatment of RDH12-associated Leber congenital amaurosis (RDH12-LCA), a rare inherited retinal disease that causes progressive vision loss and blindness beginning in early childhood.

The IND clearance enables Opus Genetics to advance OPGx-RDH12 into clinical development, marking an important achievement in the Company's collaboration with the Global RDH12 Alliance, which brings together patient advocacy organizations RDH12 Fund for Sight in the United States and Eyes on the Future in the United Kingdom. The partnership was established in July 2025 with the goals of accelerating development of OPGx-RDH12 and bringing a potential treatment to patients living with this devastating condition.

“We are pleased to advance our third gene therapy pipeline program into clinical development and plan to initiate a Phase 1/2 trial this quarter,” said George Magrath, M.D., Chief Executive Officer, Opus Genetics. “RDH12-LCA causes progressive vision loss beginning at a very young age, underscoring the urgency of developing treatments that may preserve vision before further deterioration occurs. Receiving IND clearance for OPGx-RDH12 represents an important step toward bringing a potentially transformative gene therapy to children and families affected by this devastating disease. We are grateful for the collaboration and commitment of our partners at the Global RDH12 Alliance, which has been instrumental in advancing this program into the clinic.”

"Bringing a treatment to the members of the RDH12-LCA community has been the stated goal of The RDH12 Fund for Sight since its founding more than a decade ago,” said Mathew Pletcher, Ph.D., Board member of the RDH12 Fund for Sight and father to a 20-year-old child living with RDH12-LCA. "From the foundational work, funded by patient dollars, in the lab of Dr. Jean Bennett through today’s announcement, the RDH12-LCA community has been collaborating with partners to ensure the delivery a potentially vision-saving therapy to the clinic."

“This is what true co-development looks like,” said Silvia Cerolini, Chief Executive Officer of Eyes on the Future and mother of a child affected by RDH12-LCA. “Our RDH12 patient organizations and Opus have pooled resources, capabilities and risk to bring this rare gene therapy into the clinic, combining venture philanthropy, scientific innovation and a patient-driven sense of urgency. We have been working toward this moment for many years, and we are grateful to Opus for being a true partner. We believe this model can become a blueprint for bringing gene therapies to rare disease communities, and one that other patient organizations can follow.”

Under the strategic collaboration announced in July 2025, the Global RDH12 Alliance committed up to $1.6 million toward the development of OPGx-RDH12, with eligible development costs reimbursed as activities are completed subject to certain diligence obligations and milestones. The organizations are working together on the clinical and regulatory strategy for the program, integrating the perspectives and experiences of patients and families directly into its development.

About RDH12-LCA and OPGx-RDH12

RDH12-LCA is a rare form of childhood blindness affecting an estimated 30,900 people globally. Mutations in the RDH12 gene impair protein function in the retina, leading to early visual decline, often with structural retinal changes by age two, and rapid progression during adolescence. OPGx-RDH12 is an investigational adeno-associated virus (AAV)-based gene therapy designed to deliver a functional copy of the RDH12 gene directly to photoreceptor cells in the retina. Preclinical studies of OPGx-RDH12 in cell and mouse models have demonstrated restoration of RDH12 activity and functional improvements, supporting clinical evaluation of the therapeutic candidate.

About The RDH12 Fund for Sight

The RDH12 Fund for Sight is a registered 501(c)(3) not-for-profit organization based in the United States. The RDH12 Fund for Sight was founded for the express purpose of connecting and supporting families impacted by RDH12-LCA and to ensure that significant funds are devoted to the study and development of treatments for LCA caused by mutations in RDH12.

About Eyes on the Future

Eyes on the Future is a UK-based not-for-profit organization supporting research into rare diseases and eye diseases, with a specific focus on RDH12 inherited retinal dystrophies. Founded by Enrico and Silvia, whose 12-year-old child is affected by RDH12-LCA, Eyes on the Future is a registered company limited by guarantee in England and Wales (No. 13956181) and a registered charity (No. 1198330). More information is available at www.eyesonthefuture.org.uk

.

About Opus Genetics

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with OPGx-RDH12 cleared to enter the clinic, and additional candidates targeting, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, N.C. For more information, visit www.opusgtx.com

.

Forward-Looking Statements

This press release contains certain statements that are not statements of historical fact and are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “strive,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Such statements include, but are not limited to, statements related to the Company’s plans for the clinical development of OPGx-RDH12, including the anticipated timing of initiation, and the design, of the Phase 1/2 clinical trial of OPGx-RDH12; the therapeutic potential of OPGx-RDH12, including its potential to preserve vision or otherwise treat RDH12-LCA; the significance of preclinical data for OPGx-RDH12 and whether such data will be predictive of clinical results; the Company’s collaboration with the Global RDH12 Alliance and the potential of this partnership to accelerate development of OPGx-RDH12 and bring a potential treatment to patients living with this devastating condition; the Company’s ability to satisfy diligence obligations and meet development milestones under its agreement with the Global RDH12 Alliance and the potential of the collaboration model to be replicated to bring other gene therapies to rare disease communities; and the Company’s expectations regarding its business prospects and results of operations. There can be no assurance that the Company’s planned Phase 1/b clinical trial of OPGx-RDH12 will be initiated on the anticipated timeline or at all, or that OPGx-RDH12 will be shown to be safe or effective or receive regulatory approval.. The forward-looking statements contained herein are subject to certain risks and uncertainties posed by many factors and events that could cause the Company’s actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2025, its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and in the Company’s other filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. The Company undertakes no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise.

Contacts:

Investors

Jenny Kobin

Remy Bernarda

IR Advisory Solutions

[email protected]

**Media

**Kimberly Ha

KKH Advisors

917-291-5744

[email protected]

Prompts

Opus Genetics, Inc. (ticker IRD), listed in United States.

Company History

Date Change Detail
Oct 24, 2024 Renamed OCUPHIRE PHARMA, INC. → OPUS GENETICS, INC.
Nov 9, 2020 Renamed REXAHN PHARMACEUTICALS, INC. → OCUPHIRE PHARMA, INC.
May 16, 2005 Renamed CORPORATE ROAD SHOW DOT COM INC → REXAHN PHARMACEUTICALS, INC.
— Former tickers OCUP

ETFs Holding Opus Genetics, Inc.

ETF Weight in ETF Shares Market value As of
SURI 0.74% 125,000 $ 506.25K Nov 17, 2026